Baseline left atrial volume as a potential predictor of trastuzumab related cardiotoxicity in her 2 positive breast cancer patients

被引：0
|
作者：
Dolci, G. [1 ]
Bergamini, C. [1 ]
Benfari, G. [1 ]
Torelli, F. [1 ]
Ghiselli, L. [1 ]
Rossi, A. [1 ]
Trevisani, L. [1 ]
Truong, S. [1 ]
Vinco, G. [1 ]
La Russa, F. [2 ]
Molino, A. [2 ]
Vassanelli, C. [1 ]
机构：
[1] Univ Verona, Sect Cardiol, Dept Med, Verona, Italy
[2] Civil Hosp Maggiore Borgo Trento, Oncol, Verona, Italy
来源：
EUROPEAN HEART JOURNAL | 2017年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P569
引用
收藏
页码：99 / 99
页数：1
相关论文
共 50 条
  • [41] Significance of value of biomarkers troponine I and NT-proBNP in evaluation of potential cardiotoxicity of Trastuzumab in patients with HER2 positive breast cancer
    Zdrale, Z.
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 12 : S288 - S289
  • [42] Effect of HER2/neu 655 polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients.
    Blancas, Isabel
    Martin, Celia
    Legeren, Marta
    Martos, Michel
    Sequero, Silvia
    Mut-Salud, Nuria
    Gallardo, Emma
    Manuel Garrido, Jose
    Rodriguez-Serrano, Fernando
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Hypersensitivity reactions and cardiac toxicity related to Trastuzumab in HER2 positive breast cancer patients
    Ayres, L. R.
    Campos, M. S. D. A.
    Gozzo, T. D. O.
    Ungari, A. Q.
    de Andrade, J. M.
    Pereira, L. R. L.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (06) : 1336 - 1336
  • [44] Deceleration capacity of heart rate predicts trastuzumab-related cardiotoxicity in patients with HER2-positive breast cancer: A prospective observational study
    Feng, Yanying
    Qin, Zhenhua
    Yang, Zhijun
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (01) : 93 - 98
  • [45] Baseline Troponin Level and Cardiac Toxicity in HER2-positive Early Breast Cancer Patients Receiving Trastuzumab
    Canale, Maria laura
    Casolo, Giancarlo
    Donati, Sara
    Bisceglia, Irma
    Puccetti, Cheti
    Amoroso, Domenico
    Venturini, Elio
    Maurea, Nicola
    Turazza, Fabio maria
    Camerini, Andrea
    IN VIVO, 2023, 37 (05): : 2139 - 2146
  • [46] RETROSPECTIVE ANALYSIS OF CARDIAC MEDICATIONS IN THE PREVENTION OF CARDIOTOXICITY IN TRASTUZUMAB-TREATED HER2 POSITIVE BREAST CANCER PATIENTS
    Moey, Melissa
    Liles, Darla K.
    Carabello, Blase
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 694 - 694
  • [47] PROSPECTIVE EVALUATION OF CIRCULATING BIOMARKERS AS PREDICTORS OF CARDIOTOXICITY IN PATIENTS WITH HER2-POSITIVE BREAST CANCER RECEIVING ANTHRACYCLINES AND TRASTUZUMAB
    Yu, Anthony F.
    Knezevic, Andrea
    Moskowitz, Chaya
    Dang, Chau
    Ramanathan, Lakshmi
    Oeffinger, Kevin
    Liu, Jennifer
    Steingart, Richard
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 691 - 691
  • [48] Trastuzumab Use Modest in Patients With HER2-Positive Breast Cancer
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (05) : 339 - 339
  • [49] Neratinib after trastuzumab in patients with HER2-positive breast cancer
    Hasegawa, Takahiro
    Uno, Hajime
    Wei, Lee-Jen
    LANCET ONCOLOGY, 2016, 17 (05): : E176 - E176
  • [50] Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer
    Vaynrub, Anna
    Mishalani, Leila
    Raikhelkar, Jayant
    Crew, Katherine D.
    CARDIO-ONCOLOGY, 2024, 10 (01)
12345